BRAD GINEVAN: Open Payments
NPI 1285732016 · SHEFFIELD, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,635 in 113 payments from 21 companies in 2025. Trend: 2023 $2,661 · 2024 $2,588 · 2025 $1,635
Food & beverage: $1,635
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 18 | $352 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $255 |
| ABBVIE INC. | 29 | $218 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $136 |
| Axsome Therapeutics, Inc. | 7 | $129 |
| PFIZER INC. | 5 | $76 |
| Novo Nordisk Inc | 4 | $66 |
| Phathom Pharmaceuticals, Inc. | 4 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Corcept Therapeutics | 2 | $43 |
Products named: RELISTOR, AIRSUPRA, CAPLYTA, BREZTRI, Auvelity, UBRELVY, QULIPTA, FARXIGA.
Industry payments across AL — which companies pay providers there.
